Informace o projektu
Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response
(ONCOBIOME)
- Kód projektu
- 825410
- Období řešení
- 1/2019 - 6/2024
- Investor / Programový rámec / typ projektu
-
Evropská unie
- Horizon 2020
- Health, demographic change and wellbeing (Societal Challenges)
- Fakulta / Pracoviště MU
-
Přírodovědecká fakulta
- Mgr. Eva Budinská, Ph.D.
- Mgr. Anna Pačínková, Ph.D.
- Maria Persico, PhD
- Viacheslav Petrov
- doc. Ing. Vlad Popovici, PhD
- Luis Fernando Santa Guzman, PhD
- Spolupracující organizace
-
Masarykův onkologický ústav Brno
INSTITUT GUSTAVE ROUSSY
- Odpovědná osoba Prof. Laurence Zitvogel
Beyond its role in regulating multiple physiological functions that impact health, the intestinal metagenome is implicated in cancer initiation, progression and responses to therapies, even for extraintestinal neoplasia. Hence, there is an urgent need to fully identify and functionally characterize minimalist commensal ecosystems relevant to cancer, with reliable and robust methods, to validate cancer-associated gut microbiome fingerprints of high clinical relevance, and to develop diagnosis tools that will become part of the oncological arsenal for the optimization and personalization of therapy. Based on retro-and pro-spective studies, with large discovery and validation cohorts enrolling >9,000 cancer patients across 10 countries, ancillary to ongoing innovative clinical trials or FDA/EMA approvals across 4 frequent cancer types, ONCOBIOME will pursue the following aims: 1/ identify and validate core or cancer-specific Gut OncoMicrobiome Signatures (GOMS) associated with cancer occurrence, prognosis, response to, or progression on, therapy (polychemotherapy, immune checkpoint inhibitors, dendritic cell vaccines) or adverse effects, 2/ decipher the functional relevance of these cancer-associated gut commensal ecosystems in the regulation of host metabolism, immunity and oncogenesis, 3/ integrate these GOMS with other oncology hallmarks (clinics, genomics, immunomics, metabolomics) 4/ design optimal companion tests, based on those integrated signatures to predict cancer occurrence and progression. With high carat interdisciplinary experts, ONCOBIOME expects to validate cancer or therapy-specific Gut OncoMicrobiome Signatures (GOMS) across breast, colorectal, melanoma and lung cancers adjusting for covariates, to unravel the mode of action of these GOMS in innovative platforms, thus lending support to the design of cancer preventive campaigns using well characterized pre-and pro-biotics.
Publikace
Počet publikací: 4
2023
-
A Fecal MicroRNA Signature by Small RNA Sequencing Accurately Distinguishes Colorectal Cancers: Results From a Multicenter Study
Gastroenterology, rok: 2023, ročník: 165, vydání: 3, DOI
-
IntOMICS: A Bayesian Framework for Reconstructing Regulatory Networks Using Multi-Omics Data
Journal of Computational Biology, rok: 2023, ročník: 30, vydání: 5, DOI
2022
-
Using empirical biological knowledge to infer regulatory networks from multi-omics data
BMC Bioinformatics, rok: 2022, ročník: 23, vydání: 1, DOI
2021
-
Colorectal Tumour Mucosa Microbiome Is Enriched in Oral Pathogens and Defines Three Subtypes That Correlate with Markers of Tumour Progression
Cancers, rok: 2021, ročník: 13, vydání: 19, DOI